A Resof-Hepcfix tablet consist of two most conspicuous active substances which will exhibits anti-viral activity against hepatitis C viral infection. Two components like; Sofosbuvir; Daclatasvir Resof-Hepcfix tablet which is approved by FDA and it is first established product comes under the combination of sofosbuvir and Daclatasvir. Usually Daclatasvir is not used as monotherapy; it must be concomitant with sofosbuvir for potent anti-viral activity. Resof-Hepcfix is a single dose therapy, with minimal adverse effects. Resof-Hepcfix has better effectiveness in chronic hepatitis condition.
400mg & 60mg
Resof-Hepcfix indicated for
The primary indications of Resof-Hepcfix tablets are;
Involved in advance or long-lasting hepatitis C viral infection mainly associated to genotype I or III.
The only drawback occurred in Resof-Hepcfix tablet taking patients;
There is a chance of reduction in virologic response rate in patients who are all receiving Resof-Hepcfix for 12 weeks in HCV genotype III conditions. The usage of Resof-Hepcfix is only occurred in adolescents; not in pediatric patients. The potency of Resof-Hepcfix tablet has not been evaluated in pediatric patients.
Resof-Hepcfix exhibits anti-viral activity by (mechanism)
Resof-Hepcfix in addition to tablet has two segments Sofosbuvir and Daclatasvir
Sofosbuvir is a prohibitor of nucleotide simple, particularly precludes HCV non-auxiliary protein 5B RNA subordinate RNA polymerase. Sofosbuvir experience intracellular digestion, which deliver pharmacologically dynamic compound like uridine simple triphosphate. Sofosbuvir mediated into RNA of hepatitis C infection with the assistance of NS5B polymerase. This may goabout as chain eliminator.
Non-basic 5A protein is fundamental for viral duplication. Daclatasvir meddle with the action of NS5A protein, this may prompt viral annihilation.
Maximum plasma concentration time of;
Sofosbuvir 0.5 to 2 hours
Daclatasvir 2 hours
No effect of food, may take with or without food
Bioavailability of Daclatasvir 67% The human plasma protein bounds to; Sofosbuvir: 61 to 65% Daclatasvir: 99%
Sofosbuvir is metabolized by liver, using carboxyl esterase 1 or cathepsin A as a catalyst During metabolism sofosbuvir is converted into active uridine triphosphate Daclatasvir is a substrate of CYP3A.
Before starting the therapy with Resof-Hepcfix tablets, patient undergone hepatic function test and examine the lab measurements. If patient suspected with HBV infection, must be investigate by counting the hepatitis B surface antigen & hepatitis B core antibody. Resof-Hepcfix tablet is containing 60mg of Daclatasvir & 400mg of sofosbuvir. The usual dosage of Resof-Hepcfix is one tablet to be given orally as once a day. Resof-Hepcfix tablet should be administered with or without food.
Patients with HCV genotype I infection:
Without cirrhosis or child Pugh A or B (compensated cirrhosis): The usual dose of Resof-Hepcfix is one tablet should be given orally as once a day. Decompensated cirrhosis (child Pugh C): The usual recommended dosage is one tablet of Resof-Hepcfix should be administered orally as once daily by combining with ribavirin.
Patients with HCV genotype III infection:
Without cirrhosis or child Pugh A or B (compensated cirrhosis): The recommended dose of Resof-Hepcfix is one tablet should be given orally as once a day. In compensated, decompensated cirrhosis or post liver transplantation: The recommended dosage of Resof-Hepcfix tablet is one tablet to be administered orally as a single dose.
Dosage recommendation of Ribavirin:
Patient with HCV related genotype I or III: The recommended dose of ribavirin is 600mg should be taken as an initial dose, followed by increasing up to 1000mg. Patient with compensated cirrhosis: The dosage of ribavirin should be based on the body weight of the patients. Based on the weight of the HCV suspected patients; At least 75kg: 1200mg of ribavirin should be taken Below 75kg: 1000mg should be taken Ribavirin should be administered with or without food.
There are no known antitoxins forResof-Hepcfix overdose. Therapy of overdose with Resof-Hepcfix should consist of general supportive measures, containchecking of vital signs and observation of the patient’s clinical status.
Resof-Hepcfix causing side effects
Pruritus, Asthenia, Anemia, Loss of appetite, Flu like syndrome, Pyrexia, Diarrhea, Fatigue, Headache, Insomnia, Nausea, Rash, Neutropenia, Myalgia, Irritability, Pancytopenia, Rising level of bilirubin, creatine kinase, lipase, AST & ALT HBV reoccurrence may occur Serious bradycardia while combining with amiodarone
Resof-Hepcfix safety precautions
Use cautiously in the patients who are suspected with HBV infection, there is a chance of elevating the exposure of HBV reoccurrence in the patient co infected with HCV & HBV
Serious bradycardia occurs while concurrent use of Resof-Hepcfix tablet with amiodarone.
Increasing risk of loss of therapeutic effect occurs while concurrently use Resof-Hepcfix tablet with P-gp inducers or inhibitors Severe adverse may occur due to drug interaction, to prevent this problem avoid this type of combinational therapy.
Resof-Hepcfix warning signs
Hepatitis B viral infection reactivation occurs in patient co infected with HCV & HBV; to avoid this problem patients must be undergone liver function test.
This may occur due to fail to take HBV anti-viral agents.
The major demerit of Resof-Hepcfix tablet is loss of virological response rate in patients with HCV infection related to genotype I or III with the duration of therapy for 12 weeks. Serious life-threatening condition like bradycardia occurs while using Resof-Hepcfix with amiodarone.